Abstract
Common diseases like essential hypertension or diabetes mellitus are complex as they are polygenic in nature, such that each genetic variation only has a small influence on the disease. Genes operates in integrated networks providing the blue-print for all biological processes and conditional of the complex genotype determines the state and dynamics of any trait, which may be modified to various extent by non-genetic factors. Thus, diseases are heterogenous ensembles of conditions with a common endpoint. Numerous studies have been performed to define genes of importance for a trait or disease, but only a few genes with small effect have been identified. The major reasons for this modest progress is the unresolved heterogeneity of the regulation of blood pressure and the shortcomings of the prevailing monogenic approach to capture genetic effects in a polygenic condition. Here, a two-step procedure is presented in which physiological heterogeneity is disentangled and genetic effects are analyzed by variance decomposition of genetic interactions and by an information theoretical approach including 162 single nucleotide polymorphisms (SNP) in 84 genes in the sphingolipid metabolism and related networks in blood pressure regulation. As expected, almost no genetic main effects were detected. In contrast, two-gene interactions established the entire sphingolipid metabolic and related genetic network to be highly involved in the regulation of blood pressure. The pattern of interaction clearly revealed that epistasis does not necessarily reflects the topology of the metabolic pathways i.e., the flow of metabolites. Rather, the enzymes and proteins are integrated in complex cellular substructures where communication flows between the components of the networks, which may be composite in structure. The heritabilities for diastolic and systolic blood pressure were estimated to be 0.63 and 0.01, which may in fact be the maximum heritabilities of these traits. This procedure provide a platform for studying and capturing the genetic networks of any polygenic trait, condition, or disease.
Introduction
Essential hypertension refers to hypertension with no known cause, affects approximately 30% of the adult population, and is a major risk factor for stroke, coronary incidences, and end-stage renal disease (Kearney et al., ). Several clinical and biochemical variables has been shown to be correlated to hypertension (Wang et al., ; Parikh et al., ; Singer and Setaro, ), but still the causes of essential hypertension remains elusive (Weder, ).
Blood pressure levels in a population constitutes an ensemble of polygenic conditions (Shih and O'Connor, ) meaning that the blood pressure is regulated by a plethora of integrated biochemical and physiological processes that are blue-printed in the genome (Fenger et al., ). Hypertension arise as a consequence of variations in these networks of intermingled processes increasing the propensity for developing hypertension conditional to a variable extent on non-genetic factors. Thus, blood pressure levels spans a scale of genetic information conditional on which non-genetic factors may influence the clinical outcome. However, the genetic causes of essential hypertension are largely unknown.
Several approaches including genome-wide association (GWA) studies (reviewed in Deng, ; Hamet and Seda, ; Shih and O'Connor, ) have extensively been used to define the genetics of blood pressure regulation and hypertension, but only a few potential genes have been associated with essential hypertension (Deng, ; Hamet and Seda, ; WTCCC, ; Ehret et al., ; Shih and O'Connor, ; Adeyemo et al., ; Levy et al., ; Newton-Cheh et al., ). In particular the large GWA studies have been somewhat disappointing as only sketchy information about the networks regulating the blood pressure have been provided. This may not be that surprising as the vast majority of analysis have been done as a search of monogenic effects in a case-control framework. Such approaches are at best simplifications of basic biological principles i.e., all biological processes are defined by interacting components (enzymes, metabolites etc…). For instance, epistasis (in extensio the interactions of the genes in the entire network) may be the most important genetic contribution to the variance of a trait, not the main effects (Fenger et al., , ; Shao et al., ; Huang et al., ). Considering that the number of variations discovered runs in the millions, most networks (the sizes of which we do not know) will harbor thousands of variations in coding and non-coding, regulatory areas in principle defining as many networks as the number of combinations of variations. Some of these are not viable and hence never expressed, but still the number of networks are staggering (Fenger, ). This genetic heterogeneity is reflected in phenotypic heterogeneity, and hence a condition as hypertension is merely a clinical endpoint of diverse states of genetic networks and metabolic pathways in blood pressure regulation. Several approaches to include gene-gene interactions has been suggested including genetic algorithms and machine learning techniques (e.g., Routman and Cheverud, ; Culverhouse et al., ; Bureau et al., ; Zeng et al., ; Alvarez-Castro and Carlborg, ; Kang et al., ; Cantor et al., ; Wang et al., ), but the drawbacks are that specific genetic models are required, arbitrary data-reduction procedures are widely used, and many of the approaches requires that main effects are detected thereby excluding most genes from analysis.
Previously we addressed the problem of resolving physiological heterogeneity of a population by implementing a latent class/structural equation modeling (LCA/SEM) framework using common physiological variables generally assumed to be related to cardiovascular conditions (Fenger et al., ). This approach revealed 14 distinct subpopulations with different propensity to develop hypertension embracing subpopulations with no hypertensive cases at all to subpopulations where the majority or all the subjects presented themself with hypertension. The significance of the genetic network of the sphingolipid metabolism in hypertension were evaluated by variance decomposition with focus on the de novo synthesis of sphingolipids and in particular the ceramide/sphingosine-1-phosphate rheostat (Fenger et al., ). The influence of sphingolipids on the vascular tone and hypertension is controversial as opposing vasodilatory and vasoconstrictive effects have been reported (Johns et al., ; Rosskopf et al., ; Alewijnse and Peters, ; Pavoine and Pecker, ; Feletou et al., ), particularly for the essential metabolites in the ceramide/sphingosine-1 phosphate (Cer/S1P) rheostat (Igarashi et al., ; Li et al., ; Ohmori et al., ; Hemmings, ; Alewijnse and Peters, ). In most tissues S1P has vasoconstrictive effects (Hemmings, ), but the regulation of vascular tone is vessel (organ)-dependent (Mulders et al., ; Fenger et al., ). Here, we extend our previous analysis (Fenger et al., ) including a comprehensive selection of genetic variations covering the sphingolipid metabolism and related processes (the redox and phosphatidate networks, Figure 1) and introduce an information theoretic analysis to assess the significance of genetic factors and their interaction. Even with the relatively small number of genetic variations included here the analytical procedures are highly involved, but most importantly, despite the genetic complexity of blood pressure regulation, almost all affected subjects could be captured by genotyping a few genes, although the predictive value of the compound genotypes varies considerably.
Figure 1
Materials and methods
Ethical statement
The MONICA study was conducted in accordance with the Second Helsinki Declaration and was approved by the ethics committee for Copenhagen County. Written informed consent was obtained from all participants, including permission to take part in genetic research.
Model assumptions
The physiologically heterogeneity of diastolic and systolic blood pressures was resolved by partition of the study population by combined latent class analysis and structural equation modeling (LCA/SEM) into an ensemble of 14 physiological more homogeneous subpopulations, i.e., more accurate phenotypes were defined (Fenger et al.,
Figure 2

The structural equation model (SEM). A simplified cartoon of the principal behind structural equation modeling (SEM). Here a cell is influenced by several “environmental” factors e.g., insulin (Ins) which induce a response in the cellular regulatory network cascade. The effect of this signal transduction is to induce or inhibit transcription of genes or genetic regulatory structures (Genomics). In addition, the signaling may directly influence the functionality of effector networks e.g., by promoting phosphorylation of effector proteins in all resulting in regulation of the blood pressure. In real life the pathway from the external factors to the ultimate response is much more complex as several cell types are involved in the local process (the vessel) and several tissues or organs will be involved (e.g., fatty acids generated in the liver) in a complex interactive network. The entire system is formulated by a complex set of matrix formulated regression algorithms, which may be proximal to the processes we actually can obtain information above or just by summary expressions. The subpopulations are then defined by simultaneous optimizing the SEM and the latent class (or rather latent profile) defining the population structure. A detailed account can be found in Muthen and Muthen (
The genome-wide genotype in a subject is fixed allocating an individual to a particular subpopulation together with subjects with similar physiological expressions. Implicitly, no subject transitions between subpopulations are possible. Only transitions from one level to another level of the blood pressure would be possible within the subpopulation, depending on the load of non-genetic factors and within limits defined by the subpopulation-specific genotype, i.e., the non-genetic factors operate conditional on a genetic framework that physiologically sets the range of a trait that cannot be exceeded. In the limit, each individual do of course defines its own subpopulation as no two individuals share the exact same genotype. However, the available physiological data have limited discriminatory power so the number of subpopulations is far less than the number of subjects included, and hence each subpopulation harbors subjects with similar, but distinct genotypes. Nevertheless, the partition of the population obtained serves its purpose to reduce variance within the subpopulations to such an extent that important parts of the genetic networks are captured.
The outcome of this approach is a classification of the subjects in the population in mutually exclusive subpopulations with distinct physiological metabolic states differing in propensity to evolve into hypertension. The best fitting model used blood pressure measurement in the supine position as the outcome (Fenger et al.,
For a detailed presentation and discussion of these complex issues, please see Fenger (
Population
The study population is the Danish leg of the international MONICA-study (Jorgensen,
Genotyping
The 353 SNPs included in this study were extracted from NCBI database and included most of the exonic SNPs in the genes in the metabolic sphingolipid network as well as SNPs from the related redox and phosphatidate networks (Figure 1). Mostly missense and frameshift mutations in the exons in the selected genes was included in the genetic analysis. However, for genes in which no missense mutations has been reported synonymous mutations were genotyped to obtain maximum coverage of the genes. The details of the genes and SNPs are listed in Tables S1a,b. The genotyping was performed by KBioscience, Hoddesdon, Hertfordshire, United Kingdom. The call-rate was above 98.5%.
Evaluation of genetic interactions
Epistasis was calculated by variance decomposition for all combinations of SNPs in all subpopulation as previously described (Fenger et al.,
Two-gene interactions are actually measures of the mutual information (Brillinger,
Case-control analysis
Comparisons of the distribution of genotypes between subpopulations (classes) were done in a classical case-control design in which each subpopulation were compared to each of the other subpopulations. Also, each subpopulation (“cases”) were compared to the remaining subjects (“controls”) in the study population. Significant two-SNP genotypes as evaluated by WMI (above) were analyzed in a case-control design in the entire population for diastolic and systolic hypertension separately.
Statistics
Basic statistics were performed in SPSS v19.0 on a PC, or in LibreCalc on the Ubunto Linux platform. Bonferoni correction for multiple testing with a nominal p-value of 0.05 were applied to all analysis, unless stated otherwise. The Python packages Numpy, Scipy and Powerlaw were used in programmed algorithms. Plots were generated by QtiPlot v 0.9.8.8 on the Ubunto Linux platform.
A parallel, multi-threaded software package for variance decomposition, analyses of epistasis, mutual information analysis and topology of the networks is under development in Python and will be freely available shortly.
Results
General description of the population
Fourteen subpopulations were previously identified by latent class/structural equation modeling (Fenger et al.,
The 353 SNPs included were all annotated as polymorphic in NCBI dbSNP database, but only 160 turned out to be polymorphic in the MONICA population (Tables S1a,b). SNPs were only included in the analyses if the minor allele frequency (MAF) was above 0.01 to limit or avoid sporadic interactions, although the such excluded interactions may be real. Anyhow, cutting MAF at 0.01 or 0.05 only change the results marginally compared to not deleting any SNPs as he vast majority of MAFs were above 0.05. However, setting the MAF to 0.1 reduced the information gained from the genes and is therefore not appropriate.
The number of significant two-SNP interactions (epistasis) did not show a consistent pattern and differs between the subpopulations. In some subpopulations, including subjects allocated with a probability of 0.7 or above, the number of interactions was highest, but this it not the case in all subpopulations (Tables S2, S3). Restricting the MAF to above 0.01 reduced the numbers of epistatic interactions estimated by the variance decomposition, but the amount of interactions were still in the thousands.
The WMI was increased (in several cases substantially) when the allocation probability was increased for all MAF levels in all classes (Tables S2, S3). However, the number of interactions passing the WMI significant test (before and after correction for multiple testing) were drastically reduced (Tables 1, 2). The reason for these behaviors are two: the change in genotype distributions as subjects with less reliable class allocation were removed, and the change in effect size of the genotypes. Increasing the allocation probability essentially reduces “noise” in the sense of non-robust classification of subjects increasing the mutual information and hence the WMI. All interactions with significant mutual information are summarized in Tables S4, S5.
Table 1
| Only SNPs with MAF of 0.01 or above is included | |||||
|---|---|---|---|---|---|
| Epistasis | WMI Bonferoni corrected | ||||
| Subpopulation | Subjects | Valid SNPs | Number | Total WMI | Number |
| 2 | 44 | 140 | 8197 | 244 | 34 |
| 3 | 143 | 68 | 1734 | 3 | 9 |
| 4 | 16 | 121 | 5058 | 318 | 16 |
| 5 | 53 | 125 | 6360 | 281 | 39 |
| 6 | 82 | 137 | 7411 | 224 | 43 |
| 7 | 85 | 135 | 6774 | 264 | 34 |
| 8 | 12 | 110 | 516 | 173 | 4 |
| 9 | 83 | 130 | 6483 | 265 | 40 |
| 10 | 23 | 124 | 6987 | 318 | 18 |
| 11 | 90 | 126 | 5724 | 257 | 41 |
| 12 | 14 | 113 | 5914 | 470 | 14 |
| 13 | 61 | 123 | 5915 | 288 | 43 |
| 14 | 16 | 117 | 3818 | 414 | 9 |
| 722 | 70,891 | 3521 | 344 | ||
| Fraction of possible epistasis | 42.60% | ||||
| WMI/epistasis ratio | 0.49% | ||||
| Unique WMI-significant interactions | 185 | 53.78% | |||
| Males | 1258 | 100 | 2911 | 8.70 | 16 |
| Females | 1251 | 69 | 1539 | 2.28 | 6 |
| 2509 | 4450 | 10.97 | 22 | ||
| WMI/epistasis ratio | 0.49% | ||||
Summary of significant interactions of WMI in diastolic blood pressure.
Table 2
| Only SNPs with MAF of 0.01 or above is included | |||||
|---|---|---|---|---|---|
| Epistasis | WMI Bonferoni corrected | ||||
| Subpopulation | Subjects | Valid SNPs | Number | Total WMI | Number |
| 2 | 44 | 140 | 8195 | 405 | 32 |
| 3 | 143 | 68 | 1752 | 5 | 11 |
| 4 | 16 | 121 | 1057 | 428 | 13 |
| 5 | 53 | 125 | 6374 | 405 | 38 |
| 6 | 82 | 137 | 7413 | 356 | 39 |
| 7 | 85 | 135 | 6752 | 490 | 36 |
| 8 | 12 | 110 | 255 | 0 | 0 |
| 9 | 83 | 130 | 6530 | 389 | 37 |
| 10 | 23 | 124 | 6984 | 546 | 18 |
| 11 | 90 | 126 | 5686 | 403 | 32 |
| 12 | 14 | 113 | 5136 | 773 | 14 |
| 13 | 61 | 123 | 5927 | 485 | 40 |
| 14 | 16 | 117 | 3586 | 661 | 9 |
| 722 | 65,647 | 5345 | 319 | ||
| Fraction of possible epistasis | 39.45% | ||||
| WMI/epistasis ratio | 0.49% | ||||
| Unique WMI-significant interactions | 182 | 57.05% | |||
| Males | 1258 | 100 | 2958 | 11.67 | 8 |
| Females | 1251 | 69 | 1548 | 2.97 | 3 |
| 2509 | 4506 | 14.64 | 11 | ||
| WMI/epistasis ratio | 0.24% | ||||
Summary of significant interactions of WMI in systolic blood pressure.
Subpopulations 3, 8, and 11 differs from in this general analysis from the other subpopulations in several ways and will be treated separately below.
Analysis of gender
Stratifying the population according to gender only provide little information about the networks. Although thousands of significant interactions were detected (59–66% of all possible) only a few accounted collectively for 50% or more of the WMI, which is anyhow low compared to the subpopulations extracted by the LCA/SEM procedure (Tables 1, 2). Four genes (GALC, FABP2, SMPD4, and ASAH2) accounted for this information.
The GALC (rs398607)/GALC(rs34362748) interaction was prominent in both gender and particular for diastolic blood pressure. The explained variance by this interaction in the gender partition was 8.7% or below. This SNP-combination was recovered in most but not all subpopulations although with very low information content (WMI). The prevalence of hypertension associated with this SNP-combination did not significantly differ from population prevalence of hypertension, however. The FABP2 (rs1511025)/FABP2 (rs1799883) interaction was recovered in some subpopulations, but all with very low WMI and none significantly influenced the prevalence of hypertension.
Interestingly, the two dominating interactions in the subpopulations (the SPHK1 and ASAH1 interactions, Tables 1, 2, and see below) were not detected, suggesting that, accepting the assumption that blood pressure states and hypertension are heterogeneous physiological conditions, simply partition of the population by gender was not sufficiently discriminatory. This is in accordance with LCA/SEM model implemented to define the subpopulations (Fenger et al.,
Analysis of subpopulations
Variance decomposition
One of the most striking findings was that two interactions were present as the top-2 interactions in most subpopulations (Tables 1, 2): the SPHK1 (rs8176328)/SPHK1 (rs2247856) interaction were detected with the restrictions imposed (MAF of 0.01 and allocation probability 0.9) in all subpopulations except in subpopulation 3 for diastolic blood pressure and subpopulations 3 and 8 for systolic blood pressure. Similarly, the ASAH1 (rs1049874)/ASAH1 (rs1071645) interaction was detected as a top-2 interaction in all subpopulations except in the subpopulations 3, 8, and 11 for both diastolic and systolic blood pressure. This ASAH1 interaction was not detected in subpopulations 3 and 8 at all (Tables S4, S5). These two top interactions (termed ubiquitous interactions) were consistently detected regardless of MAF and allocation probability level except in subpopulations 3, 8, and 11 (Tables S2, S3).
In subpopulation 8 the interactions determined by variance decomposition were increasing as the allocation probability was raised to 0.7, but was drastically reduced when allocation probability threshold was set at 0.9 and above with a concomitant reduction in number of subjects in this class from 88 to 12. The number of interactions were reduced considerably to approximately 7.8 and 3.8% (diastolic and systolic blood pressure, respectively) of the maximum amount of interaction encountered at a probability allocation threshold of 0.7 (Tables S2, S3).
Regression of the relative genotype/phenotype variance on the phenotypic variance for the two-SNP genotypes almost perfectly fit a straight line (R2 ~ 0.98), that is the larger the genetic influence of the two-SNP genotypes the lower phenotypic variance and hence a lower impact of non-genetic factors, supporting the assumption that the genetic network sets the level and the range of variation possible for an individual as well in a homogenous subpopulation. It could be expected that the relative epistasis was correlated to the genotypic variance too, but the correlation turned out to be were low (not shown). The two two-SNP genotypes with the highest genotype/phenotype variance (and lowest phenotypic variance) are the SPHK1 rs8176328/rs2247856 genotypes (distance 12 nt) and the ASAH1 rs1049874/rs1071645 genotypes (distance 1482 nt). This is consistently seen for all subpopulations except subpopulation 3 and partly subpopulations 8 and 11 (Tables S4, S5).
Weighted mutual information, WMI
In all, only approximately 0.5% of all interactions detected by variance decomposition was recovered after filtering for significant mutual information (Tables 1, 2). A total of 344 significant WMIs were detected for diastolic blood pressure and 319 for systolic blood pressure (Tables S4, S5, respectively) distributed over the subpopulations. Of these 663 WMIs 182 represents unique two-SNP interactions in the entire ensemble of subpopulations for both traits, while additional three were detected for diastolic blood pressure only, amounting to more than 50% of all WMI-significant interactions for the two blood pressure measurements separately (Tables 1, 2, and Table S8). This is almost 4-fold more interactions compared to partition of the study population only by gender (not shown).
The total WMI were at similar levels for the subpopulations except for subpopulation 3 and 8 using the restrictions imposed (see below). Slightly more than one third of the two-SNP WMIs (39.2% for diastolic blood pressure and 35.5% for systolic blood pressure) were private in the sense that they only occurred in one subpopulation (Tables S4, S5). Most of these are common to both traits but have very low WMI. A few interactions did however have a substantial WMI particularly in subpopulations 4, 8, 12, and 14, and thus may have a significant role in defining the subpopulations (Tables S4, S5).
Subpopulation 3 showed a different pattern of interactions as the ubiquitous interactions were not captured. The number of valid SNPs i.e., non-monomorph SNPs which are in HWE was reduced significantly to almost half compared to the other subpopulations. The vast majority of SNPs were excluded because they “turned” monomorph and hence non-informative, which particularly included the SNPs defining the ubiquitous genotypes except the SPHK1 rs8176328. ASAH1 was not detected at all. Consequently the major source of information was missing and the information retained by the remaining SNPs was extremely low amounting to 1% or less compared to the other subpopulations (Tables 1, 2). The low WMI and genetic variance precluded this subpopulation from further analysis as any inferences would be highly unreliable.
Three ASAH1/ASAH1 interactions were detected by the WMI analysis in subpopulation 8 but not the ubiquitous combination mentioned above and they were not significant even at the nominal level of 0.05 (not shown). In contrast, the ubiquitous SPHK1/SPHK1 interaction was detected for diastolic blood pressure but not for systolic blood pressure though (Tables S4, S5). However, relaxing the strict allocation probability threshold from 0.9 to 0.7 the two ubiquitous interactions were detected with high probability in both diastolic and systolic blood pressure in this subpopulation and the general pattern of interactions was similar to the other subpopulations. Thus, the general allocation probability thresholds was somewhat arbitrarily set at 0.9, but a few lower allocation probability thresholds should be tested to avoid serious loss of information, as in this case could lead to the erroneous conclusion that the sphingolipid metabolism do not influence the blood pressure regulation in subpopulation 8, while in fact the contrary is the truth.
The ubiquitous SPHK1/SPHK1 interaction was highly significant for diastolic and systolic blood pressure and possessed high WMI values in subpopulation 11. In contrast, although ASAH1/ASAH1 interactions were detected by the WMI analysis, the ubiquitous combination above were not detected. The ASAH1/ASAH1 interactions was however “substituted” by a SMPD4 (rs76033185/ rs79875317; 20,267 nucleotides apart) with high WMI. SMPD4 codes for the neutral membrane sphingomyelinase 3 generating ceramide, while ASAH1 codes acid ceramidase generating sphingosine in the salvage pathway (Figure 1). Thus, at least theoretically, the ceramide/sphingosine-1 phosphate rheostat in subpopulation 11 is balanced in favor of ceramides, while the opposite is the case of all the other subpopulations except subpopulation 3. Hence, at least two basically different metabolic pathways in the sphingolipid metabolism is associated with blood pressure regulation.
Trait comparisons
Comparisons of trait difference conditional on two-SNP genotypes are shown in Tables S6, S7 for diastolic and systolic blood pressure, respectively. At the nominal significance level 336 and 304 two-SNP genotype combinations differed in diastolic and systolic mean values, respectively. However, only two comparisons remained significant after correction for multiple testing for diastolic blood pressure. Both were combinations of SNPs in SPHKAP, sphingosine kinase 1 interacting or anchoring protein. They were detected in just short of 50% of the diastolic hypertensive subjects. In the case of systolic blood pressure four SNPs in four genes were significant, but the prevalence in systolic hypertensive subjects were rather low. Nevertheless, one combination, the GALC rs398607 CC genotype combined with the CERK rs36211083 TT genotype, was associated with increased systolic blood pressure (see also Table 3) and may be clinically useful.
Table 3
| Fraction (%)* | ||||||||
|---|---|---|---|---|---|---|---|---|
| SNP1 | Gene1 | Genotype1 | SNP2 | Gene2 | Genotype2 | p-value | Genotype | Population |
| DIASTOLIC BLOOD PRESSURE | ||||||||
| Genotypes above the threshold | ||||||||
| rs865832 | SGPL1 | TT | rs12770335 | SGPL1 | GG | 0.0138 | 50 | 1.62 |
| rs309087 | LPPR5 | CC | rs5186 | AGTR1 | CC | 0.0279 | 50 | 1.3 |
| rs3734462 | AGPAT4 | TT | rs1799983 | NOS3 | TT | 0.0279 | 50 | 1.3 |
| rs1799883 | FABP2 | AA | rs1799983 | NOS3 | TT | 0.0220 | 45.45 | 1.62 |
| rs28385609 | SMPDL3A | TT | rs2003149 | KDSR | GA | 0.0182 | 36.36 | 2.6 |
| rs309087 | LPPR5 | CC | rs5186 | AGTR1 | CA | 0.0401 | 34.78 | 2.6 |
| rs243887 | SPTLC3 | TT | rs1071645 | ASAH1 | AG | 0.0123 | 26.97 | 7.79 |
| rs243887 | SPTLC3 | TT | rs1049874 | ASAH1 | GA | 0.0130 | 26.67 | 7.79 |
| rs41292584 | SMPDL3A | CT | rs1799983 | NOS3 | GG | 0.0308 | 25 | 7.47 |
| rs41292584 | SMPDL3A | CT | rs3739709 | LPAR1 | CC | 0.0313 | 23.53 | 10.39 |
| rs1138439 | PPAP2C | TT | rs12195587 | ELOVL2 | TC | 0.0451 | 23.39 | 9.42 |
| rs1138439 | PPAP2C | TT | rs2003149 | KDSR | GA | 0.0377 | 23.13 | 11.04 |
| rs3811514 | SPHKAP | GG | rs3828161 | SPHKAP | AA | 0.0371 | 22.17 | 14.61 |
| Genotypes below the threshold | ||||||||
| rs1799983 | NOS3 | GT | rs2566514 | NOS3 | CC | 0.0008 | 10.18 | 16.23 |
| rs3739968 | ASAH2B | GG | rs1071645 | ASAH1 | GG | 0.0341 | 10.16 | 6.17 |
| rs285 | LPL | TT | rs320 | LPL | GT | 0.0224 | 10.14 | 7.14 |
| rs3739968 | ASAH2B | GG | rs1049874 | ASAH1 | AA | 0.0314 | 9.94 | 5.84 |
| rs1799983 | NOS3 | GT | rs3828161 | SPHKAP | GA | 0.0123 | 9.87 | 7.47 |
| rs1130233 | AKT1 | AG | rs3828161 | SPHKAP | GA | 0.0215 | 9.84 | 6.17 |
| rs6109692 | SPTLC3 | CT | rs2241883 | FABP1 | GA | 0.0430 | 9.79 | 4.55 |
| rs11657217 | ENPP7 | GG | rs3734462 | AGPAT4 | TC | 0.0479 | 6.67 | 1.3 |
| rs6511701 | S1PR5 | GT | rs1695 | GSTP1 | GG | 0.0358 | 6.15 | 1.3 |
| rs11657217 | ENPP7 | GG | rs3170633 | GCLM | GG | 0.0010 | 4.35 | 1.3 |
| rs4880 | SOD2 | TT | rs11657217 | ENPP7 | GG | 0.0253 | 4.17 | 0.65 |
| rs5186 | AGTR1 | CC | rs67319648 | PPAPDC1A | CT | 0.0485 | 3.23 | 0.32 |
| SYSTOLIC BLOOD PRESSURE | ||||||||
| Genotypes above the threshold | ||||||||
| rs398607 | GALC | CC | rs36211083 | CERK | TT | 0.0130 | 100 | 0.67 |
| rs398607 | GALC | TT | rs1805078 | GALC | TC | 0.0124 | 80 | 0.89 |
| rs1130233 | AKT1 | AA | rs3828161 | SPHKAP | GG | 0.0302 | 66.67 | 0.89 |
| rs243887 | SPTLC3 | TT | rs2241883 | FABP1 | GG | 0.0206 | 50 | 2.01 |
| rs1799983 | NOS3 | GT | rs3828161 | SPHKAP | GG | 0.0236 | 42.86 | 2.68 |
| rs1130435 | FABP6 | CC | rs7157599 | DEGS2 | GG | 0.0296 | 38.64 | 3.8 |
| rs7850023 | MIR4668 | AG | rs5186 | AGTR1 | CC | 0.0400 | 36.73 | 4.03 |
| rs5186 | AGTR1 | AA | rs2301022 | GCLM | AA | 0.0169 | 33.63 | 8.5 |
| rs1476387 | SMPD2 | TT | rs3739709 | LPAR1 | CT | 0.0312 | 33.33 | 7.61 |
| rs3739968 | ASAH2B | GA | rs4918 | AHSG | GG | 0.0178 | 33.07 | 9.4 |
| rs285 | LPL | CC | rs1695 | GSTP1 | AA | 0.0136 | 31.43 | 14.77 |
| rs12195587 | ELOVL2 | TC | rs1476387 | SMPD2 | GG | 0.0183 | 30.84 | 14.77 |
| rs1138439 | PPAP2C | TT | rs7302981 | CERS5 | CC | 0.0408 | 30.77 | 10.74 |
| rs6511701 | S1PR5 | GT | rs1695 | GSTP1 | AA | 0.0123 | 30.63 | 18.57 |
| rs285 | LPL | CC | rs7157599 | DEGS2 | AA | 0.0321 | 29.8 | 16.33 |
| rs12195587 | ELOVL2 | TC | rs8176328 | SPHK1 | AG | 0.0182 | 29.77 | 20.58 |
| rs12195587 | ELOVL2 | TC | rs2247856 | SPHK1 | TC | 0.0195 | 29.65 | 21.03 |
| rs12195587 | ELOVL2 | TC | rs698912 | COL4A3BP | AA | 0.0407 | 28.42 | 23.71 |
| Genotypes below the threshold | ||||||||
| rs6511701 | S1PR5 | GG | rs1868158 | SMPD3 | AG | 0.0492 | 19.35 | 23.94 |
| rs12195587 | ELOVL2 | CC | rs2247856 | SPHK1 | TC | 0.0338 | 19.21 | 26.17 |
| rs11657217 | ENPP7 | CC | rs402348 | KDSR | CA | 0.0359 | 17.34 | 9.62 |
| rs285 | LPL | TT | rs328 | LPL | CC | 0.0183 | 17.32 | 11.86 |
| rs1799983 | NOS3 | GG | rs3828161 | SPHKAP | GA | 0.0119 | 16.33 | 8.95 |
| rs3811515 | SPHKAP | GT | rs16824283 | SPHKAP | CG | 0.0137 | 16.32 | 8.72 |
| rs1138439 | PPAP2C | CC | rs36211083 | CERK | TC | 0.0488 | 15.18 | 3.8 |
| rs398607 | GALC | TT | rs36211083 | CERK | TC | 0.0191 | 13.13 | 2.91 |
| rs1049874 | ASAH1 | AA | rs4808863 | CERS1 | TT | 0.0237 | 12.16 | 2.01 |
| rs1071645 | ASAH1 | GG | rs4808863 | CERS1 | TT | 0.0237 | 12.16 | 2.01 |
| rs243887 | SPTLC3 | TT | rs1049874 | ASAH1 | AA | 0.0268 | 9.8 | 1.12 |
| rs243887 | SPTLC3 | TT | rs1071645 | ASAH1 | GG | 0.0192 | 9.43 | 1.12 |
| rs320 | LPL | GG | rs328 | LPL | CC | 0.0282 | 9.09 | 0.89 |
| COMMON TO BOTH DIASTOLIC AND SYSTOLIC BLOOD PRESSURE | ||||||||
| Genotypes above the respective thresholds | Diastolic/systolic blood pressure | |||||||
| rs79875317 | SMPD4 | AA | rs1695 | GSTP1 | GG | 0.002/0.001 | 71.43/54.17 | 1.62/2.91 |
| rs76033185 | SMPD4 | GG | rs1695 | GSTP1 | GG | 0.008/0.003 | 66.67/83.33 | 1.30/1.12 |
| rs1138439 | PPAP2C | TT | rs36211083 | CERK | TT | 0.044/0.038 | 44.44/55.56 | 1.30/1.12 |
| rs2297568 | SPTLC1 | AG | rs3828161 | SPHKAP | GG | 0.010/0.001 | 37.50/54.17 | 2.92/2.91 |
| rs12888666 | GALC | AA | rs1695 | GSTP1 | AA | 0.049/0.013 | 25.00/35.71 | 6.82/6.71 |
| rs1130233 | AKT1 | AA | rs243887 | SPTLC3 | TT | 0.014/0.015 | 50.00/60.00 | 1.62/134 |
| rs11657217 | ENPP7 | CG | rs402348 | KDSR | CA | 0.016/0.043 | 22.27/29.3 | 18.51/16.78 |
| Genotypes below the respective thresholds | ||||||||
| rs3734462 | AGPAT4 | TC | rs1049874 | ASAH1 | AA | 0.020/0.043 | 9.73/16.76 | 5.84/6.94 |
| rs11657217 | ENPP7 | GG | rs402348 | KDSR | CA | 0.013/0.043 | 4.76/29.30 | 0.97/16.78 |
Prevalence of affected for two-SNP genotypes.
Prevalence of diastolic hypertension in the population 16.13% (threshold).
Number of subjects with diastolic hypertension captured by the significant genotypes 253 (82.14% of all affected).
Prevalence of systolic hypertension in the population 23.40% (threshold).
Number of subjects with systolic hypertension captured by the significant genotypes 436 (97.54% of all affected).
Genotypes in bold, missense mutations; genotypes in italic, synonymous mutations.
For gene abreviations, please see Supplemental Data Table S1a.
Freqencies of the affected by the two-SNP genotype (Genotype) and frequencies of the two-SNP genotype in the population (Population).
Heritabilities
The heritability of blood pressure regulation as a function of the WMI is plotted in Figure 3. The three curve fitting methods polynomial, Boltzmann (sigmoid), and Gaussian gave almost the same heritabilities for blood pressure regulation except for subpopulation 3. The broad sense (all genetic variance included) heritabilities h2 = genotypic variance/phenotypic variance were estimated to be 0.626/0.012 for both diastolic and systolic blood pressure. The Boltzmann fit gave slightly higher values (0.70 and 0.69 for diastolic and systolic blood pressure, respectively). Subpopulation 8 was included in these calculation using a allocation probability threshold of 0.7 rather than 0.9, but still the curve fittings converged in a few iterations for the Boltzman and Gauss fits. The only difference was that the correlation between heritability and phenotypic variance showed a exponential decay (R2 ~ 0.98) in contrast to the remaining subpopulations, where the correlation was linear (R2 ~ 0.98). In contrast, subpopulation 3 did not fit into this general pattern. The heritability implied by the sphingolipid metabolism was only ~0.07, but still significant.
Figure 3

Association between relative epistasis and WMI. The plots shows the heritability (Geno/Pheno) of the diastolic blood pressure as a function of the weighted mutual information (the plots of systolic blood pressure are similar). Subpopulation 8 was evaluated at an allocation threshold of 0.7 in contrast to 0.9 for all the other subpopulation (see Text for discussion). The three fitted plots [polynomial, Boltzmann (sigmoid), and Gaussian] were almost overlapping. Apart from the ubiquitous ASAH1 and SPHK1 haplotypes there is a difference in the ranking of the next interactions between the subpopulations. Similar differences in patterns were seen for the other subopulations.
The two ubiquitous interactions defined by ASAH1 and SPHK1 were supplying the most information in all subpopulations except in subpopulation 3. These two genes are pivotal in the ceramide/sphingosine-1 phosphate rheostat: ASAH1 codes for acid ceramidase generating sphingosine and SPHK1 phosphorylate sphingosine to generate sphingosine-1 phosphate (Figure 1). The remaining interactions had various impact on WMI, the most notable differences illustrated by comparing subpopulation 8 and 12 (Figure 3). SMPD4, coding a neutral sphingomyelinase operating at the plasma membrane generating ceramide is prominent in subpopulation 8, while the acid sphingomyelinase (SMPDL3B) operating in the salvage pathway, i.e., in the lysosomes, did carry major information of the sphingolipid network in subpopulation 12. Also, the redox network (represented by GALC) seems to be of major importance in subpopulation 8.
Interactions/heritabilities not annotated in Figure 3 can be found in Tables S4, S5.
Case-control analysis
Assessment of differences in single-SNP or single-gene genotype distributions between subpopulations or individual subpopulations and the rest of the study population resulted in detection of some significant SNPs. However, less than 5% of the valid SNPs appeared to be potential discriminatory, no consistent pattern of SNPs were detected, and the p-values were mostly marginal, and no significant differences remained after correction for multiple testing.
In contrast, when two-SNP combinations were analyzed in the case-control design, 1755 and 1728 two-SNP combinations were detected for diastolic and systolic blood pressure, respectively, when WMI-significant interactions were exclusively included. Of these 34 and 40 were significant associated with the prevalence diastolic and systolic hypertension, respectively (Table 3). Approximately two-thirds were significantly associated with increased prevalence of diastolic or systolic hypertension applying the general accepted cut-off of 90 mmHg and 140 mmHg for diastolic and systolic blood pressure, respectively. The remaining interactions were associated with decreased prevalence. Most, but not all interacting SNPs turned out to be homozygous, suggesting the traditional concept of recessive genes, i.e., that genes (or rather genetic variations) has to be homozygous to affect a trait. The vast majority of two-SNP interactions were specific to diastolic or systolic blood pressure, respectively (Table 3). Only 9 of the 65 (unique) interactions (13.8%) were common to both blood pressure measurements.
Network interactions
The interaction pattern is very complex even with the relative few two-SNP/gene interactions having an impact on the prevalence of hypertension (Table 3). The complexity extends to the metabolic pathways, but we only have a rudimentary knowledge of the regulation of these networks and pathways. In addition, there were striking difference in interaction patterns between diastolic and systolic blood pressure (Table 3). A discussion of the interactions is therefore highly tentative so only a few interactions are evaluated (see Table S1).
The two SNP-interactions, SPHK1 and ASAH1, are fixed at two haplotypes or alleles as only two homozygotes and one composite heterozygote were detected out of nine theoretically possible genotypes. The distance between the two ASAH1 SNPs is 1484 bp, while it is only 12 bp between the two SPHK1 SNPs (see however Table S2). These genotypes represented by far the largest amount of information (WMI) but did not influence the prevalence of hypertension (Table 3). In addition, there was no significant difference in mean values between the three genotypes for each of the genes and could not per se set different levels of blood pressure. However, as described above, the higher the WMI the larger amount of phenotypic variance is determined by the genotypes, i.e., the more the trait is fixed in the genome. SPHK1 and ASAH1 presented themself with the highest WMI, which can be interpreted as these SNPs or genes provides the most information of the genetic influence of the trait variation, but do not necessary set the actual level of the blood pressure. The epistasis defined by these two genes are intragenic defining three basic haplotypes each.
Topology
A plethora of network descriptors are available, but here we limit the discussion to the node degree distribution and the much applied power law and Poisson distributions of the WMI data sets. The power law is here defined as p(x)~x−α and has obtained quite an interest as many data-structures seems to follow this simple distribution with the α-value generally estmated to be in the interval (2,3). Most of the classes do have α-values in this range, with a few classes outside this range for the nominal significant WMI (Table S9). However, only approximately 8–59% of the WMI values were captured by the power law or by any other heavy-tailed distributions tested (lognormal, exponential). The latter was improved considerably after correction for multiple testing, but apart from the lower α-values encountered, the variance of the α-values increased substantially. The nominal WMI data points not included in the power law distribution did not fit any of several other tested distributions (normal, lognormal, exponential, uniform, Poisson, and several more). However, in WMI data set corrected for multiple testing the remaining data after extractionof the power law data did fit Poisson distributions.
The degree sequences of the SNPs and genes for the WMI data sets show a similar pattern of distributions as for the WMI data sets themselves. The gene degree sequences for diastolic and systolic blood pressure are almost identical (Table S10). Several genes in the sphingolipid metabolic network seems to qualify as hubs including sphingosine kinase 1 (SPHK1), its regulatory protein SPHKAP, ceramide synthase 4 and galactocerebrosidase. Acid ceramidase (ASAH1) appears as a hub in the salvage pathway, and this enzyme together with SPHK1 are the two metabolic “endpoints” in the regulation of the blood pressure (see above and Figure 2). The source of fatty acids for synthesis of sphingolipids seems to be derived from circulating triglycerides suggested by the hub-like status of lipoprotein lipase (LPL) and fatty acid binding protein 2 (FABP2) (Table S10). Finally, the ROS and NO metabolisms are of central importance in the blood pressure regulation (Igarashi and Michel,
It should be kept in mind that the above conclusions are for the most part conjectural founded on the “naive” assumption that a higher degree of a gene equals importance. The real importance of a gene is the information it supplies by interaction with the other genes. Nevertheless, the above analysis is supportive of the conclusions obtained from the WMI analysis.
Discussion
All populations are heterogenous due to the vast genetic variation present, and all genes only operates in integrated networks (Fenger,
Detection of genes and extra-genic variations of importance relies heavily on the reliability and accuracy of the phenotypes. This is clearly seen by comparison of the gender-based partition with the physiologically modeled partition, where there was more than a 300-fold increase in genetic information provided by the interactions, and more than a 15-fold increase in the number of significant interactions when corrected for multiple testing (Tables 1, 2). Most intriguingly, none of the few interactions detected in the gender partition analysis was recovered under more stringent conditions as influencing the prevalence of hypertension (Table 3). This could (cautiously) be interpreted as false positive results due to the coarse-grained partition of the population imposed by gender, but more importantly the partition of the population into more homogenous subpopulations using physiological variables in an latent class/structural equation modeling (other partition approaches are possible) is a prerequisite of obtaining information about the genetics of a trait or condition to any substantial and interesting extent.
The WMI introduced here is a measure of the amount of information that the interacting genes provide about the trait. This measure is tightly related to the relative genetic variance in particular including all two-SNP/gene interactions (Figure 3). As can be seen and discussed above the ubiquitous SPHK1 and ASAH1 genotypes provided the most information about the sphingolipid network and could be considered as genetic information hubs that express their effects (or information) not exclusively by themself but only through interaction with other genes, i.e., they represent the maximal information and genetic variance accounted for by the entire network. Thus, depending on information contained in a two-SNP interaction the relative impact increases non-linearly to a maximum which is the amount of genetic influence (heritability) on the trait. The hierarchal and non-linear accumulation of relative genetic variance can be understood in same way as two-SNP/gene interactions: two-SNP composite genotypes can be considered as a single entity that will not be functional outside its context i.e., the network or modules in the network, but may provide detectable although small influence on the trait. Any two sets of two-SNP genotypes shares some mutual information about the network i.e., some information is already present, and for this reason either genetic variance or information are cumulative. The argument goes on to the next level and ultimately the information and hence the explained genetic variance asymptotically levels of and reach a maximum, that is the heritability of the trait as depicted in Figure 3.
It was expected that the node degree sequences of the genes were distributed as a power law or Poisson distributed, but to the contrary only a small fractions of the genes were captured by the power law distribution. Most of the genes did not conform to any of several continuos distributions and appears totally random distributed. This trend is confirmed in analysis of effects sizes and variances in which the data sets on average contains more than 5000 samples. However, when only data corrected for multiple testing were included a bipartite structure appeared: the power law distributed data did only capture a fraction of the data, while the Poisson distribution did not fit the entire set of data (corrected for multiple testing); rather, the data set can be split in two components, one captured by the power law, the other by Poisson distributions (as in the famous and widely applied Erdös-Rényi random graph, Erdös and Rényi,
The influence of the sphingolipid network on the blood pressure regulation was quite large, while the impact of the phosphatidate and redox networks seemed to be limited. Caution should be observed with this conclusion as the selection of genes, mostly from the sphingolipid metabolic network, may have been fortuitous. Other genes or combination of genes could harbor more information than the ubiquitous genotypes above, but the heritability will only increase marginally if at all considering the fits shown in Figure 3. Thus, although possible, it is not likely that any gene-interactions will surpass the ubiquitous genotypes in collated information content. The exception is subpopulation 3, in which the sphingolipid metabolic network only have a minor influence on the blood pressure. The phosphatidate and redox networks could be of importance as only a limited number of SNPs were included, but other networks and pathways are of course possible. The patterns of interactions differs between the subpopulations, but the sphingolipid metabolic network is established to be central to the regulation of the blood pressure.
Only a few of the valid SNPs have previously been associated with any clinical condition (Tables S1a,b). Some of the candidate genes were not included in the analysis as the SNPs turned out to be monomorphic, and for this reason the coverage is not entirely comprehensive (which must be assumed also to be the case for the other networks). In particular, several of the ceramidases, fatty acid binding proteins and S1P- and LPA-receptors were not included. The number of interactions influencing the prevalence of hypertension is rather modest, but may be substantial underestimated as important participants in the networks are missing. Thus, the number of SNPs and genes involved is expected to increase when the inclusion of variations and genes become more comprehensive.
There have been contrasting views about the importance of epistasis in genetic systems. Crow argues that epistasis is unimportant in polygenic directional selection (Crow,
Generally, the physiological and biochemical interpretation of the interactions revealed in the present study are highly theoretical as both metabolic and functional interactions are possible. Most probably, many of the interactions, apart from the flux of metabolites in the networks, may include elements of stereogenic interactions of the components generating integrated complexes of enzymes (Lehner,
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
Benjamin Sedoc is thanked for his help in programming the software required for this study to be possible.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fgene.2015.00084/abstract
References
1
AdeyemoA.GerryN.ChenG.HerbertA.DoumateyA.HuangH.et al. (2009). A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 5:e1000564. 10.1371/journal.pgen.1000564
2
AlewijnseA. E.PetersS. L. M. (2008). Sphingolipid signalling in the cardiovascular system: good, bad or both?Eur. J. Pharmacol. 585, 292–302. 10.1016/j.ejphar.2008.02.089
3
Alvarez-CastroJ. M.CarlborgO. (2007). A unified model for functional and statistical epistasis and its application in quantitative trait Loci analysis. Genetics176, 1151–1167. 10.1534/genetics.106.067348
4
AritaM. (2005). Scale-freeness and biological networks. J. Biochem. 138, 1–4. 10.1093/jb/mvi094
5
BrillingerD. R. (2004). Some data analysis using mutual information. Braz. J. Probab. Stat. 18, 163–182.
6
BureauA.DupuisJ.FallsK.LunettaK. L.HaywardB.KeithT. P.et al. (2005). Identifying SNPs predictive of phenotype using random forests. Genet. Epidemiol. 28, 171–182. 10.1002/gepi.20041
7
CantorR. M.LangeK.SinsheimerJ. S. (2010). Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet. 86, 6–22. 10.1016/j.ajhg.2009.11.017
8
CrowJ. F. (2010). On epistasis: why it is unimportant in polygenic directional selection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 365, 1241–1244. 10.1098/rstb.2009.0275
9
CulverhouseR.SuarezB. K.LinJ.ReichT. (2002). A perspective on epistasis: limits of models displaying no main effect. Am. J. Hum. Genet. 70, 461–471. 10.1086/338759
10
DehmerM.Emmert-StreibF.GrabnerM. (2014). A computational approach to construct a multivariate complete graph invariant. Inf. Sci. 260, 200–208. 10.1016/j.ins.2013.11.008
11
DengA. Y. (2007). Genetic basis of polygenic hypertension. Hum. Mol. Genet. 16 Spec. No. 2, R195–R202. 10.1093/hmg/ddm126
12
EhretG. B.MorrisonA. C.O'ConnorA. A.GroveM. L.BairdL.SchwanderK.et al. (2008). Replication of the Wellcome Trust genome-wide association study of essential hypertension: the family blood pressure program. Eur. J. Hum. Genet. 16, 1507–1511. 10.1038/ejhg.2008.102
13
ErdösP.RényiA. (1960). On evolution of random graphs. Publ. Math. Inst. Hung. Acad. Sci. 5:17.
14
FeletouM.HuangY.VanhoutteP. M. (2011). Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br. J. Pharmacol. 164, 894–912. 10.1111/j.1476-5381.2011.01276.x
15
FengerM. (2008). Modelling genetic and physiological heterogeneity, in Genetic Inheritance Patterns, ed KimuraR. (New York, NY: Nova Science Publisher), 75–123.
16
FengerM. (2012). Genetic networks in hetogeneous populations. J. Genet. Disor. Genet. Rep. 1:1000e104. 10.4172/2327-5790.1000e104
17
FengerM. (2014). Next generation genetics. Front. Genet. 5:322. 10.3389/fgene.2014.00322
18
FengerM.LinnebergA.JorgensenT.MadsbadS.SobyeK.Eugen-OlsenJ.et al. (2011). Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension. BMC Genet. 12:44. 10.1186/1471-2156-12-44
19
FengerM.LinnebergA.WergeT.JorgensenT. (2008). Analysis of heterogeneity and epistasis in physiological mixed populations by combined structural equation modelling and latent class analysis. BMC Genet. 9:43. 10.1186/1471-2156-9-43
20
GhelliA.PorcelliA. M.FacchiniA.HreliaS.FlamigniF.RugoloM. (2002). Phospholipase D1 is threonine-phosphorylated in human-airway epithelial cells stimulated by sphingosine-1-phosphate by a mechanism involving Src tyrosine kinase and protein kinase Cdelta. Biochem. J. 366, 187–193. 10.1042/BJ20020264
21
HametP.SedaO. (2007). Current status of genome-wide scanning for hypertension. Curr. Opin. Cardiol. 22, 292–297. 10.1097/HCO.0b013e328187b502
22
HemmingsD. G. (2006). Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch. Pharmacol. 373, 18–29. 10.1007/s00210-006-0046-5
23
HuangW.RichardsS.CarboneM. A.ZhuD.AnholtR. R. H.AyrolesJ. F.et al. (2012). Epistasis dominates the genetic architecture of Drosophila quantitative traits. Proc. Natl. Acad. Sci. U.S.A. 109, 15553–15559. 10.1073/pnas.1213423109
24
HutterM.ZaffalonM. (2005). Distribution of mutual information from complete and incomplete data. Comput. Stat. Data Anal. 48, 633–657. 10.1016/j.csda.2004.03.010
25
IgarashiJ.MichelT. (2009). Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc. Res. 82, 212–220. 10.1093/cvr/cvp064
26
IgarashiJ.ThatteH. S.PrabhakarP.GolanD. E.MichelT. (1999). Calcium-independent activation of endothelial nitric oxide synthase by ceramide. Proc. Natl. Acad. Sci. U.S.A. 96, 12583–12588. 10.1073/pnas.96.22.12583
27
JohnsD. G.WebbR. C.CharpieJ. R. (2001). Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle: a possible mechanism for augmented cell proliferation. J. Hypertens. 19, 63–70. 10.1097/00004872-200101000-00009
28
JorgensenT. (1987). Prevalence of gallstones in a Danish population. Am. J. Epidemiol. 126, 912–921.
29
KangG.YueW.ZhangJ.CuiY.ZuoY.ZhangD. (2008). An entropy-based approach for testing genetic epistasis underlying complex diseases. J. Theor. Biol. 250, 362–374. 10.1016/j.jtbi.2007.10.001
30
KearneyP. M.WheltonM.ReynoldsK.MuntnerP.WheltonP. K.HeJ. (2005). Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223. 10.1016/S0140-6736(05)17741-1
31
LahiriS.FutermanA. H. (2007). The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64, 2270–2284. 10.1007/s00018-007-7076-0
32
LehnerB. (2011). Molecular mechanisms of epistasis within and between genes. Trends Genet. 27, 323–331. 10.1016/j.tig.2011.05.007
33
LevyD.EhretG. B.RiceK.VerwoertG. C.LaunerL. J.DehghanA.et al. (2009). Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41, 677–687. 10.1038/ng.384
34
LiH.JunkP.HuwilerA.BurkhardtC.WallerathT.PfeilschifterJ.et al. (2002). Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation106, 2250–2256. 10.1161/01.CIR.0000035650.05921.50
35
Lima-MendezG.vanH. J. (2009). The powerful law of the power law and other myths in network biology. Mol. Biosyst. 5, 1482–1493. 10.1039/b908681a
36
MuldersA.MathyM. J.Meyer zu HeringdorfD.ter BraakM.HajjiN.OlthofD.et al. (2009). Activation of sphingosine kinase by muscarinic receptors enhances NO-mediated and attenuates EDHF-mediated vasorelaxation. Basic Res. Cardiol. 104, 50–59. 10.1007/s00395-008-0744-x
37
MuthenL. K.MuthenB. O. (2004). Mplus User's Guide, 3rd Edn. Los Angeles, CA: Muthén & Muthén.
38
NacherJ. C.AkutsuT. (2007). Recent progress on the analysis of power-law features in complex cellular networks. Cell Biochem. Biophys. 49, 37–47. 10.1007/s12013-007-0040-7
39
Newton-ChehC.JohnsonT.GatevaV.TobinM. D.BochudM.CoinL.et al. (2009). Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41, 666–676. 10.1038/ng.361
40
OhmoriT.YatomiY.OsadaM.KazamaF.TakafutaT.IkedaH.et al. (2003). Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58, 170–177. 10.1016/S0008-6363(03)00260-8
41
OmoG.PennoG.PucciL.LucchesiD.PratoS. D.PedrinelliR. (2014). Q192R paraoxonase (PON)1 polymorphism, insulin sensitivity, and endothelial function in essential hypertensive men. Clin. Med. Insights Cardiol. 8, 57–62. 10.4137/CMC.S15493
42
ParikhN. I.PencinaM. J.WangT. J.BenjaminE. J.LanierK. J.LevyD.et al. (2008). A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann. Intern. Med. 148, 102–110. 10.7326/0003-4819-148-2-200801150-00005
43
PavoineC.PeckerF. (2009). Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc. Res. 82, 175–183. 10.1093/cvr/cvp030
44
PhillipsP. C. (2008). Epistasis - the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 9, 855–867. 10.1038/nrg2452
45
RasmussenA. L.OkumuraA.FerrisM. T.GreenR.FeldmannF.KellyS. M.et al. (2014). Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science346, 987–991. 10.1126/science.1259595
46
RosskopfD.SchurksM.RimmbachC.SchafersR. (2007). Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch. Pharmacol. 374, 429–469. 10.1007/s00210-007-0133-2
47
RoutmanE. J.CheverudJ. M. (1997). Gene effects on a quantitative trait: two-locus epistatic effects meassured at moicrosatellite markers and at estimated QTL. Evolution51, 1654–1662. 10.2307/2411217
48
SchneidmanE.BerryM. J.SegevR.BialekW. (2006). Weak pairwise correlations imply strongly correlated network states in a neural population. Nature440, 1007–1012. 10.1038/nature04701
49
ShaoH.BurrageL. C.SinasacD. S.HillA. E.ErnestS. R.O'BrienW.et al. (2008). Genetic architecture of complex traits: large phenotypic effects and pervasive epistasis. Proc. Natl. Acad. Sci. U.S.A. 105, 19910–19914. 10.1073/pnas.0810388105
50
ShihP. A.O'ConnorD. T. (2008). Hereditary determinants of human hypertension: strategies in the setting of genetic complexity. Hypertension51, 1456–1464. 10.1161/HYPERTENSIONAHA.107.090480
51
ShlensJ.FieldG. D.GauthierJ. L.GrivichM. I.PetruscaD.SherA.et al. (2006). The structure of multi-neuron firing patterns in primate retina. J. Neurosci. 26, 8254–8266. 10.1523/JNEUROSCI.1282-06.2006
52
SingerG. M.SetaroJ. F. (2008). Secondary hypertension: obesity and the metabolic syndrome. J. Clin. Hypertens. (Greenwich)10, 567–574. 10.1111/j.1751-7176.2008.08178.x
53
TangA.JacksonD.HobbsJ.ChenW.SmithJ. L.PatelH.et al. (2008). A maximum entropy model applied to spatial and temporal correlations from cortical networks in vitro. J. Neurosci. 28, 505–518. 10.1523/JNEUROSCI.3359-07.2008
54
Tunstall-PedoeH.KuulasmaaK.MahonenM.TolonenH.RuokokoskiE.AmouyelP. (1999). Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet353, 1547–1557. 10.1016/S0140-6736(99)04021-0
55
WangT. J.GonaP.LarsonM. G.LevyD.BenjaminE. J.ToflerG. H.et al. (2007). Multiple biomarkers and the risk of incident hypertension. Hypertension49, 432–438. 10.1161/01.HYP.0000256956.61872.aa
56
WangZ.LiuT.LinZ.HegartyJ.KoltunW. A.WuR. (2010). A general model for multilocus epistatic interactions in case-control studies. PLoS ONE5:e11384. 10.1371/journal.pone.0011384
57
WederA. B. (2007). Genetics and hypertension. J. Clin. Hypertens. (Greenwich)9, 217–223. 10.1111/j.1524-6175.2007.06587.x
58
WonJ. S.SinghI. (2006). Sphingolipid signaling and redox regulation. Free Radic. Biol. Med. 40, 1875–1888. 10.1016/j.freeradbiomed.2006.01.035
59
WTCCC. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature447, 661–678. 10.1038/nature05911
60
ZengZ. B.WangT.ZouW. (2005). Modeling quantitative trait loci and interpretation of models. Genetics169, 1711–1725. 10.1534/genetics.104.035857
Summary
Keywords
hypertension, sphingolipids, phosphatidate metabolism, redox metabolism, genetic networks, mutual information, epistasis, heritability
Citation
Fenger M, Linneberg A and Jeppesen J (2015) Network-based analysis of the sphingolipid metabolism in hypertension. Front. Genet. 6:84. doi: 10.3389/fgene.2015.00084
Received
05 December 2014
Accepted
17 February 2015
Published
04 March 2015
Volume
6 - 2015
Edited by
Noor Ahmad Shaik, King Abdulaziz University, Saudi Arabia
Reviewed by
Bruna De Felice, University of Naples II, Italy; Kondapalli Kasturi, Acharya Nagarjuna University, India
Copyright
© 2015 Fenger, Linneberg and Jeppesen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mogens Fenger, Department of Clinical Biochemistry and Molecular Biology, Copenhagen University Hospital, Kettegaard Alle 30, 2650 Hvidovre, Denmark mogens.fenger@regionh.dk
This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.